The estimated Net Worth of Stanley T Crooke is at least $26.1 Million dollars as of 26 January 2021. Stanley Crooke owns over 28,333 units of Ionis Pharmaceuticals Inc stock worth over $85,953 and over the last 12 years he sold IONS stock worth over $16,461,225. In addition, he makes $9,598,830 as Executive Chairman of the Board of Directors at Ionis Pharmaceuticals Inc.
Sign up
Stanley Crooke IONS stock SEC Form 4 insiders trading
Stanley has made over 53 trades of the Ionis Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 28,333 units of IONS stock worth $1,805,945 on 26 January 2021.
The largest trade he's ever made was buying 750,000 units of Ionis Pharmaceuticals Inc stock on 10 October 2012 worth over $3,000,000. On average, Stanley trades about 34,124 units every 52 days since 2012. As of 26 January 2021 he still owns at least 2,021 units of Ionis Pharmaceuticals Inc stock.
You can see the complete history of Stanley Crooke stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stanley Crooke biography
Dr. Stanley T. Crooke M.D. Ph.D. serves as Executive Chairman of the Board of Directors of the Company. He was elected Chairman of the Board in February 1991. Prior to founding Ionis, from 1980 until January 1989, Dr. Crooke worked for SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories. Dr. Crooke formerly served on the board of directors of Akcea Therapeutics, Inc., a biopharmaceutical company. The Board believes that Dr. Crooke is uniquely suited to serve on the Board primarily because, as the Chief Executive Officer and founder of Ionis, he has dedicated over 30 years to discovering and developing antisense, our technology platform. He is the named inventor on some of the key patents in the field of RNA-targeted therapeutics and has nearly 40 years of drug discovery and development experience.
What is the salary of Stanley Crooke?
As the Executive Chairman of the Board of Directors of Ionis Pharmaceuticals Inc, the total compensation of Stanley Crooke at Ionis Pharmaceuticals Inc is $9,598,830. There are no executives at Ionis Pharmaceuticals Inc getting paid more.
How old is Stanley Crooke?
Stanley Crooke is 74, he's been the Executive Chairman of the Board of Directors of Ionis Pharmaceuticals Inc since 2020. There are 3 older and 23 younger executives at Ionis Pharmaceuticals Inc. The oldest executive at Ionis Pharmaceuticals Inc is Breaux Castleman, 79, who is the Independent Director.
What's Stanley Crooke's mailing address?
Stanley's mailing address filed with the SEC is C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD,, CA, 92010.
Insiders trading at Ionis Pharmaceuticals Inc
Over the last 9 years, insiders at Ionis Pharmaceuticals Inc have traded over $32,069,332 worth of Ionis Pharmaceuticals Inc stock. The most active insiders traders include Stanley T Crooke, B Lynne Parshall, and Michael R Hayden. On average, Ionis Pharmaceuticals Inc executives and independent directors trade stock every 8 days with the average trade being worth of $445,289. The most recent stock trade was executed by Richard S Geary on 28 August 2024, trading 651 units of IONS stock currently worth $32,159.
What does Ionis Pharmaceuticals Inc do?
ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.
What does Ionis Pharmaceuticals Inc's logo look like?
Complete history of Stanley Crooke stock trades at Ionis Pharmaceuticals Inc and Regulus Therapeutics Inc
Ionis Pharmaceuticals Inc executives and stock owners
Ionis Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Stanley Crooke,
Executive Chairman of the Board of Directors -
Brett Monia,
Chief Executive Officer, Director -
Richard Geary,
Senior Vice President - Development -
Elizabeth Hougen,
Senior Vice President, Finance and Chief Financial Officer -
Patrick O'Neil,
Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary -
Joan Herman,
Director -
B. Lynne Parshall,
Director -
Dr. Brett P. Monia Ph.D.,
Founder, CEO & Director -
Dr. Stanley T. Crooke,
Scientific Advisor -
Joseph Klein,
Independent Director -
Joseph Wender,
Independent Director -
Spencer Berthelsen,
Independent Director -
Breaux Castleman,
Independent Director -
Frederick Muto,
Independent Director -
Michael Hayden,
Independent Director -
Joseph Loscalzo,
Independent Director -
Peter Reikes,
Independent Director -
B. Lynne Parshall Esq., J.D.,
Sr. Strategic Advisor & Director -
C. Frank Bennett,
Chief Scientific Officer -
Dr. Richard S. Geary,
Exec. VP & Chief Devel. Officer -
Elizabeth L. Hougen,
Exec. VP of Fin. & CFO -
Patrick R. O'Neil Esq.,
Chief Legal Officer, Gen. Counsel & Corp. Sec. -
Dr. Eric E. Swayze Ph.D.,
Exec. VP of Research -
D. Wade Walke,
Investor Relations -
Onaiza Cadoret-Manier,
Chief Corporate Development and Commercial Officer -
Eric Swayze,
Senior Vice President - Research -
Dr. C. Frank Bennett,
Exec. VP & Chief Scientific Officer -
Darren Gonzales,
Chief Accounting Officer & Sr. VP -
Joel Edwards,
VP of Corp. Operations -
Damien Mc Devitt,
Chief Business Officer -
Sarah Boyce,
Chief Business Officer -
Joseph Baroldi,
EVP, Chief Business Officer -
Kyle Jenne,
EVP, Chf GL Pdt Str Ofcr -
Allene M. Diaz,
Director -
Brian Birchler,
EVP, Corp and Development Ops -
Eugene Schneider,
EVP, Chf Clinical Develop Ofcr -
Michael J. Yang,
Director